• Genfit acquired nangibotide in summer 2026, adding a late-stage asset targeting acute-on-chronic liver failure.
• Phase 2a proof-of-concept study in ACLF planned for Q4 2026, with data targeted in 2027.
• Program leverages prior Phase 2 signals in septic shock and COVID-19, including a statistically significant mortality reduction in severe COVID-19.
• Safety package covers more than 400 subjects, with no meaningful safety differences versus placebo across four trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609141215OMX_____CNEWS_EN_GNW1001262669_en) on September 14, 2026, and is solely responsible for the information contained therein.